Neuroblastoma treatment using taurolidine hydrolysis products

摘要

Neuroblastoma is a tumor that primarily affects children. Although very high survival rates have been reported for low-risk neuroblastoma and moderate-risk neuroblastoma, current standards of care are not curative except in rare cases of surgically resectable lesions. Tauroridine has been developed as an anti-infective agent, but has been shown to have surprising oncolytic activity in cell cultures and in current rodent cancer models. The efficacy in a rodent model is superior to that in cell culture. The present invention relates to the use of taurolidine hydrolysis products (tarultam and/or taurinamide and/or methylene glycol and/or selected combinations thereof) for the treatment of neuroblastoma in childhood mammals.